» Articles » PMID: 37444405

Oral Mucosa in Cancer Patients-Putting the Pieces Together: A Narrative Review and New Perspectives

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Jul 14
PMID 37444405
Authors
Affiliations
Soon will be listed here.
Abstract

The oral mucosa is a key player in cancer patients and during cancer treatment. The increasing prevalence of cancer and cancer-therapy-associated side effects are behind the major role that oral mucosa plays in oncological patients. Oral mucositis is a debilitating severe complication caused by the early toxicity of chemo and/or radiotherapy that can restrict treatment outcome possibilities, even challenging a patient's survival. It has been referred to as the most feared cancer treatment complication. Predictive variables as to who will be affected, and to what extent, are still unclear. Additionally, oral mucositis is one of the sources of the increasing economic burden of cancer, not only for patients and their families but also for institutions and governments. All efforts should be implemented in the search for new approaches to minimize the apparently ineluctable outburst of oral mucositis during cancer treatment. New perspectives derived from different approaches to explaining the interrelation between oral mucositis and the oral microbiome or the similarities with genitourinary mucosa may help elucidate the biomolecular pathways and mechanisms behind oral mucosa cancer-therapy-related toxicity, and what is more important is its management in order to minimize treatment side effects and provide enhanced cancer support.

Citing Articles

The prevalence of oral mucositis after radiotherapy in patients with Head and Neck Cancer and its associated factors: a meta-analysis.

Li E, Zeng J, Hong F, Chen P, Yu X Clin Transl Oncol. 2024; .

PMID: 39277564 DOI: 10.1007/s12094-024-03706-y.

References
1.
Pulito C, Cristaudo A, La Porta C, Zapperi S, Blandino G, Morrone A . Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res. 2020; 39(1):210. PMC: 7542970. DOI: 10.1186/s13046-020-01715-7. View

2.
Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W . Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020; 12(4). PMC: 7232198. DOI: 10.3390/v12040372. View

3.
Lozano-Castellon J, Lopez-Yerena A, de Alvarenga J, Romero Del Castillo-Alba J, Vallverdu-Queralt A, Escribano-Ferrer E . Health-promoting properties of oleocanthal and oleacein: Two secoiridoids from extra-virgin olive oil. Crit Rev Food Sci Nutr. 2019; 60(15):2532-2548. DOI: 10.1080/10408398.2019.1650715. View

4.
van Vliet M, Harmsen H, de Bont E, Tissing W . The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog. 2010; 6(5):e1000879. PMC: 2877735. DOI: 10.1371/journal.ppat.1000879. View

5.
Stringer A, Gibson R, Bowen J, Logan R, Yeoh A, Keefe D . Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol. 2007; 5(6):259-67. View